Ladenburg Thalmann Financial Services Inc. Reduces Stake in Horizon Pharma PLC (HZNP)

Ladenburg Thalmann Financial Services Inc. lowered its position in Horizon Pharma PLC (NASDAQ:HZNP) by 54.0% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 8,543 shares of the biopharmaceutical company’s stock after selling 10,038 shares during the period. Ladenburg Thalmann Financial Services Inc.’s holdings in Horizon Pharma PLC were worth $139,000 at the end of the most recent reporting period.

Several other institutional investors have also made changes to their positions in the company. First Trust Advisors LP acquired a new position in shares of Horizon Pharma PLC during the third quarter worth about $522,000. Gilder Gagnon Howe & Co. LLC raised its position in shares of Horizon Pharma PLC by 5,252.1% in the third quarter. Gilder Gagnon Howe & Co. LLC now owns 252,031 shares of the biopharmaceutical company’s stock worth $4,569,000 after buying an additional 247,322 shares during the period. Quantbot Technologies LP acquired a new position in shares of Horizon Pharma PLC during the third quarter worth about $112,000. Wells Fargo & Company MN raised its position in shares of Horizon Pharma PLC by 15.5% in the third quarter. Wells Fargo & Company MN now owns 370,297 shares of the biopharmaceutical company’s stock worth $6,713,000 after buying an additional 49,766 shares during the period. Finally, Virginia Retirement Systems ET AL acquired a new position in shares of Horizon Pharma PLC during the third quarter worth about $337,000. Institutional investors and hedge funds own 88.09% of the company’s stock.

Institutional Ownership by Quarter for Horizon Pharma PLC (NASDAQ:HZNP)

Shares of Horizon Pharma PLC (NASDAQ:HZNP) opened at 14.37 on Friday. The firm’s 50 day moving average is $15.99 and its 200 day moving average is $17.47. The stock’s market capitalization is $2.33 billion. Horizon Pharma PLC has a 12 month low of $13.05 and a 12 month high of $23.44.

Horizon Pharma PLC (NASDAQ:HZNP) last announced its earnings results on Monday, February 27th. The biopharmaceutical company reported $0.64 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.51 by $0.13. Horizon Pharma PLC had a positive return on equity of 22.73% and a negative net margin of 1.34%. The company had revenue of $310.30 million for the quarter, compared to analyst estimates of $307.93 million. During the same period in the prior year, the company posted $0.63 EPS. Horizon Pharma PLC’s quarterly revenue was up 26.9% on a year-over-year basis. On average, equities analysts predict that Horizon Pharma PLC will post $2.18 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Ladenburg Thalmann Financial Services Inc. Reduces Stake in Horizon Pharma PLC (HZNP)” was first posted by Web Breaking News and is owned by of Web Breaking News. If you are accessing this article on another publication, it was illegally stolen and republished in violation of US & international trademark & copyright law. The legal version of this article can be read at http://www.webbreakingnews.com/2017/03/26/ladenburg-thalmann-financial-services-inc-reduces-stake-in-horizon-pharma-plc-hznp.html.

A number of equities analysts recently weighed in on the stock. Jefferies Group LLC set a $26.00 price objective on shares of Horizon Pharma PLC and gave the company a “buy” rating in a research report on Sunday, December 18th. Piper Jaffray Companies lowered their price objective on shares of Horizon Pharma PLC to $30.00 in a research report on Friday. Citigroup Inc upgraded shares of Horizon Pharma PLC from a “neutral” rating to a “buy” rating in a research report on Monday, November 28th. Zacks Investment Research upgraded shares of Horizon Pharma PLC from a “strong sell” rating to a “hold” rating in a research report on Tuesday, December 13th. Finally, Mizuho lowered shares of Horizon Pharma PLC from a “buy” rating to a “neutral” rating and lowered their price objective for the company from $30.00 to $14.00 in a research report on Friday, December 9th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $28.00.

In related news, EVP Robert Carey sold 31,808 shares of the company’s stock in a transaction that occurred on Wednesday, March 1st. The stock was sold at an average price of $16.03, for a total transaction of $509,882.24. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Corporate insiders own 2.10% of the company’s stock.

Horizon Pharma PLC Company Profile

Horizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units.

5 Day Chart for NASDAQ:HZNP

Want to see what other hedge funds are holding HZNP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Horizon Pharma PLC (NASDAQ:HZNP).

Receive News & Ratings for Horizon Pharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma PLC and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Nike Suspends Relationship with Maria Sharapova
Nike Suspends Relationship with Maria Sharapova
Rob Bironas Ex-Titans Kicker Dies in Car Crash
Rob Bironas Ex-Titans Kicker Dies in Car Crash
Ron Washington Leaves Texas Rangers Due to an Affair
Ron Washington Leaves Texas Rangers Due to an Affair
Jonathan Dwyer Falls in Line with Other Banned NFL Players
Jonathan Dwyer Falls in Line with Other Banned NFL Players
Tony Stewart Case Going to the Grand Jury
Tony Stewart Case Going to the Grand Jury
Oscar Pistorius “Blade Runner” Found Not Guilty of Murder
Oscar Pistorius “Blade Runner” Found Not Guilty of Murder


Leave a Reply

 
© 2006-2017 Web Breaking News.